Erratum.

Abstract

British Journal of HaematologyVolume 196, Issue 2 p. 453-453 ERRATUMFree Access Erratum This article corrects the following: Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases Daisuke Kaji, Manabu Kusakabe, Mamiko Sakata-Yanagimoto, Kenichi Makishima, Yasuhito Suehara, Keiichiro Hattori, Yasunori Ota, Takashi Mitsuki, Mitsuhiro Yuasa, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Yoshifumi Ubara, Koji Izutsu, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi, Go Yamamoto, Shigeru Chiba, Volume 195Issue 4British Journal of Haematology pages: 585-594 First Published online: September 23, 2021 First published: 12 January 2022 https://doi.org/10.1111/bjh.18034AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by Kaji et al. (2021),1 the data in the last two columns, second row of Table II were incorrectly converted to “31-May” and “13-June”. The data in Table II should read as follows: Table II. Clinical features of other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). Clinical characteristics All patients (n = 67) DLBCL-type (n = 36) HL-type (n = 19) Age, years, median (range) 69 (30–85) 71 (30–85) 67 (52–79) Sex (male/female), n 16/51 5/31 6/13 ECOG PS score 0–1/2–4, n 50/15 24/12 16/2 Stage I/II/III/IV, n 15/15/11/26 11/9/3/13 3/2/6/8 Underlying disease, n/N (%) Rheumatoid arthritis 62/67 (93) 33/36 (92) 18/19 (95) SLE 3/67 (4) 1/36 (3) 2/19 (11) Myasthenia gravis 1/67 (1) 0/36 (0) 0/19 (0) Polymyalgia rheumatic 1/67 (1) 0/36 (0) 1/19 (5) Polymyositis 1/67 (1) 1/36 (3) 0/19 (0) Ulcerative colitis 1/67 (1) 1/36 (3) 0/19 (0) Immunosuppressant, n/N (%) MTX 60/67 (90) 32/36 (89) 17/19 (89) MTX and biological agents 19/67 (28) 10/36 (28) 6/19 (32) Biological agents without MTX 2/67 (3) 1/36 (3) 1/19 (5) B symptoms, n/N (%) 19/65 (29) 6/36 (17) 9/18 (50) IPI score 3–5, n/N (%) 29/63 (46) 17/36 (47) 9/18 (50) Hb level ≤100 g/l, n/N (%) 12/65 (18) 5/36 (14) 5/19 (26) Elevated serum LDH level, n/N (%) 37/65 (57) 21/36 (58) 13/19 (68) Serum CRP level >5·0 mg/dl, n/N (%) 15/65 (23) 8/36 (22) 6/19 (32) Serum albumin level ≤3 g/dl, n/N (%) 14/65 (22) 8/36 (22) 4/19 (21) Lymphocyte count ≤800/µl, n/N (%) 19/64 (30) 10/35 (29) 5/18 (28) Duration of MTX administration, years, median (range) 7·4 (0·2–24·0) (n = 45) 8·4 (0·5–22·3) (n = 21) 8·2 (0·2–24·0) (n = 14) Extranodal disease, n/N (%) 32/63 (51) 20/36 (56) 6/18 (33) EBER positive, n/N (%) 39/65 (60) 15/36 (42) 15/18 (83) Died, n/N (%) 8/67 (12) 4/36 (11) 4/19 (21) CRP, C-reactive protein; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EBER, Epstein–Barr virus-encoded small RNA; Hb, haemoglobin; HL, Hodgkin lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MTX, methotrexate; SLE, systemic lupus erythematosus. We apologize for this error. The original article in the online version has been updated. REFERENCE 1KajiD, KusakabeM, Sakata-YanagimotoM, MakishimaK, SueharaY, HattoriK, et al. Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases. Br J Haematol. 2021; 195(4): 585– 94. https://doi.org/10.1111/bjh.17824Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume196, Issue2January 2022Pages 453-453 ReferencesRelatedInformation